SillaJen announced on the 21st that it received approval from the U.S. Food and Drug Administration (FDA) to amend its clinical trial plan to expand clinical trials of the anticancer drug BAL0891 to patients with acute myeloid leukemia. Acute myeloid leukemia is a type of blood cancer with a high likelihood of relapse.
SillaJen is conducting preliminary clinical trials targeting patients who are relapsed or refractory. The company plans to confirm the safety and efficacy of the anticancer drug. According to SillaJen, BAL0891 has shown to inhibit tumor growth and increase survival potential in recent preclinical trials utilizing an acute myeloid leukemia transplant model. The company noted that effects were observed even with low doses.
The BAL0891 clinical trial involves participation from the U.S. MD Anderson Cancer Center, Yale Cancer Center, and Montefiore Cancer Center. A representative from SillaJen said, "BAL0891 is a new drug substance that simultaneously inhibits phosphorylation factors TTK and PLK1," adding that the company will present new treatment alternatives and expand its pipeline into the field of blood cancer.